--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-058520" form_type: "8-K" ticker: "ABBV" cik: "0001551152" company_name: "AbbVie Inc." filed_at: "2023-05-10T23:59:59+00:00" generated_at: "2026-06-15T06:19:21.619476+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.3 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # AbbVie shareholders elect directors, ratify auditor, approve say-on-pay; supermajority amendment fails ## Summary - Class II directors Alpern, Meyer, Waddell elected with 1.14B, 1.25B, and 1.21B votes respectively. - Shareholders ratified Ernst & Young as auditor for 2023 with 1.49B votes for vs 18.7M against. - Advisory vote on executive compensation passed with 1.14B for vs 109.3M against. - Management proposal to eliminate supermajority voting failed (1.24B for, 1.29M against; needed supermajority). - Stockholder proposal for simple majority voting approved with 668.5M for vs 581.3M against. ## SEC filing metadata - accession: 0001104659-23-058520 - form_type: 8-K - ticker: ABBV - cik: 0001551152 - company_name: AbbVie Inc. - filed_at: 2023-05-10T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.3 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/tm2315162d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-058520 - JSON: https://secwatch.observer/filing/0001104659-23-058520.json - Plain text: https://secwatch.observer/filing/0001104659-23-058520.txt ## Key facts - Shareholder Votes AbbVie Inc. shareholders approved Election of Class II Directors at the 2023-05-05 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-05-05 source text: (1) The stockholders elected AbbVie’s Class II Directors with terms expiring in 2026, as follows: Name For Against Broker Non-Votes Robert J. Alpern 1,142,062,843 20,689,813 251,363,568 Melody B. Meyer 1,247,333,998 4,243,832 251,363,568 Frederick H. Waddell 1,208,836,612 14,319,844 251,363,568 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - Shareholder Votes AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on lobbying at the 2023-05-05 meeting. - Outcome: failed - Meeting: 2023-05-05 source text: (7) The stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows: For Against Abstain Broker Non-Votes 448,957,091 787,145,991 20,487,503 251,363,568 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - Shareholder Votes AbbVie Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2023-05-05 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-05-05 source text: (3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement for the 2023 annual meeting, as follows: For Against Abstain Broker Non-Votes 1,137,389,680 109,281,658 9,919,247 251,363,568 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - Shareholder Votes AbbVie Inc. shareholders rejected Amendment of certificate of incorporation to eliminate supermajority voting at the 2023-05-05 meeting. - Proposal: charter amendment - Outcome: failed - Meeting: 2023-05-05 source text: (4) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,241,106,832 11,289,016 4,194,737 251,363,568 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - Shareholder Votes AbbVie Inc. shareholders approved Stockholder proposal to implement simple majority voting at the 2023-05-05 meeting. - Outcome: passed - Meeting: 2023-05-05 source text: (5) The stockholders approved a stockholder proposal to implement simple majority voting, as follows: For Against Abstain Broker Non-Votes 668,497,335 581,300,391 6,792,859 251,363,568 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - Shareholder Votes AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on political spending at the 2023-05-05 meeting. - Outcome: failed - Meeting: 2023-05-05 source text: (6) The stockholders did not approve a stockholder proposal to issue an annual report on political spending, as follows: For Against Abstain Broker Non-Votes 187,829,409 1,052,110,624 16,650,552 251,363,568 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - Shareholder Votes AbbVie Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2023 at the 2023-05-05 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-05-05 source text: (2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2023, as follows: For Against Abstain 1,486,053,290 18,676,821 3,224,042 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm - Shareholder Votes AbbVie Inc. shareholders rejected Stockholder proposal to issue an annual report on patent process at the 2023-05-05 meeting. - Outcome: failed - Meeting: 2023-05-05 source text: (8) The stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows: For Against Abstain Broker Non-Votes 363,777,601 867,061,281 25,751,703 251,363,568 evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465923058520/0001104659-23-058520-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.